Humacyte director receives 80,000 stock options
Humacyte director Diane Seimetz received a grant of stock options covering 80,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Humacyte director Diane Seimetz received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase. Following the grant, she holds options on 80,000 shares directly. The footnote states that 25% of the options vest on June 11, 2027, with the remainder vesting in equal monthly installments through June 11, 2030.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
1 txn
Insider
Seimetz Diane
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 80,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (right to buy) — 80,000 contracts (Direct)
Holdings Before and After:
Stock Options (right to buy), 0 to 80,000 contracts (Direct)
Footnotes (1)
- F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Key Figures
Options granted: 80,000 options
Exercise price: $1.08 per share
Expiration date: June 11, 2036
+4 more
7 metrics
Options granted
80,000 options
Grant of stock options to director Diane Seimetz
Exercise price
$1.08 per share
Strike price for Humacyte common stock under the option
Expiration date
June 11, 2036
Option term end date
Underlying shares
80,000 shares
Humacyte common stock subject to options
Post-transaction derivative holdings
80,000 options
Total derivative securities held after grant
Initial vesting date
June 11, 2027
First 25% of option becomes exercisable
Monthly vesting pattern
1/48 per month
Remaining options vest monthly through June 11, 2030
Key Terms
Stock Options (right to buy), Common Stock, exercise price, vesting
4 terms
Stock Options (right to buy) financial
"security_title: Stock Options (right to buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 1.0800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/48 of the option will become exercisable on the 11th of each month"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Humacyte (HUMA) director Diane Seimetz report in this Form 4 filing?
Humacyte director Diane Seimetz reported receiving a grant of stock options for 80,000 shares of common stock. These options are a compensation-related award, not a market purchase, and give her the right to buy Humacyte shares at a fixed exercise price.
How many Humacyte (HUMA) stock options were granted to Diane Seimetz and at what price?
Diane Seimetz was granted options to buy 80,000 shares of Humacyte common stock at an exercise price of $1.08 per share. This grant represents a right to purchase shares in the future rather than an immediate stock acquisition.
What is the vesting schedule for Diane Seimetz’s Humacyte (HUMA) stock options?
The options vest 25% on June 11, 2027, then 1/48 of the grant vests monthly on the 11th through June 11, 2030. This creates a multi-year vesting schedule that ties the award to ongoing service with Humacyte.
When do Diane Seimetz’s Humacyte (HUMA) stock options expire?
The stock options granted to Diane Seimetz expire on June 11, 2036. She may exercise vested portions any time before that date, subject to plan terms, by paying the $1.08 per share exercise price to acquire Humacyte common stock.
How many Humacyte (HUMA) derivative securities does Diane Seimetz hold after this transaction?
After this grant, Diane Seimetz holds derivative securities representing 80,000 underlying shares of Humacyte common stock. All of these are from this single stock option award, held directly, with vesting spread between 2027 and 2030 under the disclosed schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
